Digital repository of Slovenian research organisations

Search the repository
A+ | A- | Help | SLO | ENG

Query: search in
search in
search in
search in

Options:
  Reset


Query: "author" (Tanja Čufer) .

41 - 50 / 121
First pagePrevious page12345678910Next pageLast page
41.
Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer : updated analysis of the observational GioTag study
Maximilian J Hochmair, Alessandro Morabito, Desiree Hao, Cheng-Ta Yang, Ross A Soo, James C-H Yang, Rasim Gucalp, Balazs Halmos, Lara Wang, Angela Märten, Tanja Čufer, 2019, original scientific article

Abstract: Aims: Overall survival (OS) and updated time to treatment failure (TTF) analysis of patients with EGFR mutation-positive (Del19, L858R) non-small-cell lung cancer who received sequential afatinib/osimertinib in the real-world GioTag study. Patients & methods: Patients had T790M-positive disease following first-line afatinib and received osimertinib treatment (n = 203). Primary outcome was TTF. The OS analysis was exploratory. Results: Median OS was 41.3 months (90% CI: 36.8-46.3) overall and 45.7 months (90% CI: 45.3-51.5) in patients with Del19-positive tumors (n = 149); 2-year survival was 80 and 82%, respectively. Updated median TTF with afatinib and osimertinib was 28.1 months (90% CI: 26.8-30.3). Conclusion: Sequential afatinib/osimertinib was associated with encouraging OS/TTF in patients with EGFR T790M-positive non-small-cell lung cancer, especially in patients with Del19-positive tumors.
Keywords: non-small cell lung carcinoma - therapy, drug therapy, afatinib, osimertinib, GioTag study
Published in DiRROS: 11.09.2020; Views: 1370; Downloads: 999
.pdf Full text (1,58 MB)
This document has many files! More...

42.
Sistemsko zdravljenje raka
Tanja Čufer, 2000, independent professional component part or a chapter in a monograph

Published in DiRROS: 28.08.2020; Views: 896; Downloads: 215
.pdf Full text (559,46 KB)

43.
Priročnik iz onkološke zdravstvene nege in onkologije
2000, dictionary, encyclopaedia, lexicon, manual, atlas, map

Keywords: diagnostika, zdravljenje, dejavniki tveganja, paliativna oskrba, psihoonkologija
Published in DiRROS: 28.08.2020; Views: 1536; Downloads: 503
.pdf Full text (15,33 MB)

44.
Rak dojke
1998, not set

Keywords: dojke, rak (medicina), patologija, epidemiologija, diagnostika, zdravljenje, rehabilitacija, zborniki
Published in DiRROS: 10.08.2020; Views: 1691; Downloads: 566
.pdf Full text (5,91 MB)

45.
Access to novel drugs for non-small cell lung cancer in Central and Southeastern Europe : a Central European Cooperative Oncology Group analysis
Tanja Čufer, Tudor Ciuleanu, Peter Berzinec, Gabriela Galffy, Marko Jakopović, Jacek Jassem, Dragana Jovanovic, Zhasmina MIhaylova, Gyula Ostoros, Christiane Thallinger, Milada Zemanova, Christoph Zielinski, 2020, original scientific article

Abstract: Background. Treatment of non-small cell lung cancer (NSCLC) improved substantially in the last decades. Novel targeted and immune-oncologic drugs were introduced into routine treatment. Despite accelerated development and subsequent drug registrations by the European Medicinal Agency (EMA), novel drugs for NSCLC are poorly accessible in Central and Eastern European (CEE) countries. Material and Methods. The Central European Cooperative Oncology Group conducted a survey among experts from 10 CEE countries to provide an overview on the availability of novel drugs for NSCLC and time from registration to reimbursement decision in their countries. Results. Although first-generation epidermal growth factor receptor tyrosine kinase inhibitors were reimbursed and available in all countries, for other registered therapies - even for ALK inhibitors and checkpoint inhibitors in first-line - there were apparent gaps in availability and/or reimbursement. There was a trend for better availability of drugs with longer time from EMA marketing authorization. Substantial differences in access to novel drugs among CEE countries were observed. In general, the availability of drugs is not in accordance with the Magnitude of Clinical Benefit Scale (MCBS), as defined by the European Society for Medical Oncology (ESMO). Time spans between drug registrations and national decisions on reimbursement vary greatly, from less than 3 months in one country to more than 1 year in the majority of countries. Conclusion. The access to novel drugs for NSCLC in CEE countries is suboptimal. To enable access to the most effective compounds within the shortest possible time, reimbursement decisions should be faster and ESMO MCBS should be incorporated into decision making.
Keywords: non-small cell lung cancer, treatment, novel drugs, Central Europe, Southeastern Europe
Published in DiRROS: 24.07.2020; Views: 1791; Downloads: 1052
.pdf Full text (341,24 KB)
This document has many files! More...

46.
47.
Sprejem in bivanje na Onkološkem inštitutu v Ljubljani
Marija Velepič, Tanja Čufer, 2002, dictionary, encyclopaedia, lexicon, manual, atlas, map

Published in DiRROS: 08.06.2020; Views: 1495; Downloads: 408
.pdf Full text (3,95 MB)

48.
49.
Tarčna terapija in imunoterapija pljučnega raka
Tanja Čufer, Lea Knez, 2015, published professional conference contribution (invited lecture)

Keywords: pljučni rak, tarčna terapija, imunoterapija
Published in DiRROS: 08.05.2020; Views: 1475; Downloads: 403
.pdf Full text (279,29 KB)

50.
Tarčno zdravljenje raka pljuč : ali smo že dosegli plato
Tanja Čufer, 2016, published professional conference contribution (invited lecture)

Keywords: rak pljuč, tarčno zdravljenje, tarčna zdravila
Published in DiRROS: 08.05.2020; Views: 1430; Downloads: 422
.pdf Full text (96,73 KB)

Search done in 0.37 sec.
Back to top